吕青①, 邹征云①②. 恶性肿瘤生物化疗的原理与临床应用*[J]. 中国肿瘤临床, 2016, 43(23): 1061-1066. DOI: 10.3969/j.issn.1000-8179.2016.23.680
引用本文: 吕青①, 邹征云①②. 恶性肿瘤生物化疗的原理与临床应用*[J]. 中国肿瘤临床, 2016, 43(23): 1061-1066. DOI: 10.3969/j.issn.1000-8179.2016.23.680
Qing LV1, Zhengyun ZOU1. Theories and clinical applications of biochemotherapy for malignant carcinomas[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(23): 1061-1066. DOI: 10.3969/j.issn.1000-8179.2016.23.680
Citation: Qing LV1, Zhengyun ZOU1. Theories and clinical applications of biochemotherapy for malignant carcinomas[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(23): 1061-1066. DOI: 10.3969/j.issn.1000-8179.2016.23.680

恶性肿瘤生物化疗的原理与临床应用*

Theories and clinical applications of biochemotherapy for malignant carcinomas

  • 摘要: 生物化疗(chemoimmunotherapy ,biochemotherapy ,CB)是将生物治疗和化学治疗联合应用于恶性肿瘤治疗领域的全新肿瘤综合治疗模式。目前国内外大量临床研究已经证实,肿瘤疫苗、单克隆抗体、免疫活性细胞及细胞因子等联合化疗的生物化疗可以显著提高抗肿瘤效应,在多种晚期难治性恶性实体肿瘤治疗中取得了较好的疗效。本文就生物化疗的原理、分类、临床应用及其存在的问题等进行综述。

     

    Abstract: Chemoimmunotherapy or biochemotherapy, the combination of chemotherapy with immunotherapy, is a novel compre -hensive treatment model for malignant carcinoma. In recent years, many clinical trials have shown that biochemotherapy is associated with an improved response rate. Such biological agents include tumor vaccines, monoclonal antibodies, cytokines, and immunocompe-tent cells. In this article, we review the theories, sort the clinical applications of novel treatments, and discuss some of the problems existing in this field.

     

/

返回文章
返回